References
- Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (pci-32765) has significant activity in patients with relapsed/refractory b-cell malignancies. J Clin Oncol. 2013;31:88–94.
- Byrd JC, Furman RR, Coutre SE, et al. Targeting btk with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
- Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with tp53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–176.
- Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120:1877–1887.
- Edwards CM. Btk inhibition in myeloma: targeting the seed and the soil. Blood. 2012;120:1757–1759.
- O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.
- Kough RH, Makary AZ. Chronic lymphocytic leukemia (cll) terminating in multiple myeloma: report of two cases. Blood. 1978;52:532–536.
- Laugen RH, Carey RM, Wills MR, et al. Hypercalcemia associated with chronic lymphocytic leukemia. Arch Intern Med. 1979;139:1307–1309.
- McMillan P, Mundy G, Mayer P. Hypercalcaemia and osteolytic bone lesions in chronic lymphocytic leukaemia. Br Med J. 1980;281:1107.
- Redmond J, 3rd, Stites DP, Beckstead JH, et al. Chronic lymphocytic leukemia with osteolytic bone lesions, hypercalcemia, and monoclonal protein. Am J Clin Pathol. 1983;79:616–620.
- Macintyre EA. Hypercalcaemia in chronic lymphatic leukaemia. Postgrad Med J. 1986;62:393–394.
- Littlewood TJ, Lydon AP, Barton CJ. Hypercalcemia and osteolytic lesions associated with chronic lymphatic leukemia (cll). J Clin Pathol. 1990;43:877.
- Seymour JF, Khouri IF, Champlin RE, et al. Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review. Am J Clin Oncol. 1994;17:360–368.
- Briones J, Cervantes F, Montserrat E, et al. Hypercalcemia in a patient with chronic lymphocytic leukemia evolving into Richter's syndrome. Leuk Lymphoma. 1996;21:521–523.
- Dunphy CH, Oza YV, Skelly ME. Previously undescribed form of b-cell chronic lymphoid leukemia with iga expression/secretion and lytic bone lesions. Am J Hematol. 1997;55:208–211.
- Wright GW, Wiesenfeld D, Seymour JF. Bilateral fracture of the mandible in chronic lymphocytic leukaemia. Case report. Aust Dent J. 1997;42:20–24.
- Robak T, Kasznicki M, Bartkowiak J, et al. Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur. Leuk Lymphoma. 2001;42:789–796.
- Narayan H, Bandyopadhyay D, Schmidt K, et al. Successful treatment of a patient with chronic lymphocytic leukaemia (cll) presenting with bony metastases with aggressive antibody and chemotherapy. Clin Lab Haematol. 2005;27:405–408.
- Langenberg JC, Bosman WM, van den Bremer J, et al. Pathological fractures in a patient with chronic lymphatic leukaemia without disease progression. BMJ Case Rep. 2015;2015.
- Vij RHA, Bensinger WI, Siegel DS, et al. Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (mm): preliminary phase 2 results. 2015. Blood(Suppl).